Biogen Idec, Isis Pharmaceuticals deal

Isis received a $10 million milestone payment from Biogen under a June 2012 deal to develop and commercialize an antisense drug candidate targeting dystrophia myotonica-protein kinase ( DMPK; DM1) to...